Venture Combats Heart Disease
May 17, 2012- Share:
Medical device company Mitralign closed on $35 million in a Series D financing led by Forbion Capital Partners, with contributions from a handful of other investors. Mitralign is developing a cardiac device for percutaneous mitral valve repair and has raised $77 million in venture funding to date. The device is for treating Functional Mitral Regurgitation, or mitral insufficiency, the most common form of valvular heart disease.
Surgical Devices
Tewksbury, MA
Developer of a catheter-based mitral valve repair system
- Share:
-
-
-
-